Ferring Pharmaceuticals to acquire reproductive-health biotech Gameto: a Fertilo patent portfolio analysis
Ferring Pharmaceuticals has agreed on October 27 to acquire Gameto in a deal potentially worth up to $1.4 billion. The upfront payment and development, regulatory, and commercial milestones were not disclosed. Gameto is a women’s reproductive health company that spun out of George Church’s lab at Harvard. Once the deal closes, the transaction will hand Ferring Gameto’s lead platform, Fertilo, an In Vitro Maturation (IVM) technology which shortens the painful and time-consuming step of maturing oocyte inside the body with daily hormone injections in conventional in vitro fertilization (IVF). With Fertilo, immature oocytes are retrieved and induced to mature outside the body in a cell culture comprising engineered ovarian support cells (OSCs) derived from human induced pluripotent stem cells (iPSCs). This technology cuts the 12-day hormonal stimulation for oocyte maturation in conventional IVF to as little as three days and alleviates the emotional and physical side effects of stimulation.
USPTO’s public records show that Gameto currently holds one issued patent (US 11,802,268) under its Fertilo platform directed to methods for inducing human oocyte maturation in vitro. Independent claim 1 in the ’268 patent recites a determining a stimulation protocol to induce oocyte production based on user sample, administering the protocol with triggering agents, retrieving the oocyte, culturing the oocyte, and monitoring oocyte maturation in vitro with a scoring metric. Dependent claims 9 and 10 are the most technically relevant to Fertilo, specifying that the cell culture metabolite for oocyte maturation comprises an iPSC-derived granulosa cell expressing high levels of steroidogenic enzymes.
The Fertilo patent family also contains several other published applications that are continuations of the ’268 patent or its abandoned parent patent. Specifically, US 2025/0368953 (’953 publication) is directed to compositions of OSCs and methods of co-culturing previously retrieved oocytes with them. The application as filed contains 286 claims with many multiple dependent claims and will likely face a restriction requirement. It covers a long set of claims on the length of follicular triggering period, the selection of follicular triggering agents, hormonal concentration ranges in blood sample, the amount of oocyte retrieved, the population size of OSCs, cryopreservation of OSCs, their compositions with diluents and excipients, kits, and a computer apparatus. Its continuation, US 2026/0146228, contains a narrower set of 30 claims that recites iPSC-derived OSCs that heterogeneously express five transcription factors, and an ex vivo composition and cell culture medium comprising them. Gameto also protects a computer apparatus and methods for rescuing immature oocyte in vitro post simulation with patent publication US 2024/0418370.
Gameto is also developing a cell-based treatment for unwanted effects of menopause through its Ameno platform. It is covered by two issued US patents. US 11,744,920 is directed to an implant and methods of manufacturing an implant for reversing ovarian decline, while US 12,758,684 claims the methods of administering the implant. The implant comprises iPSC-derived engineered OSCs that responds to the user’s natural hormonal signals and secrets a hormone in a cyclic, personalized dose. It is encapsulated in an extracellular matrix and delivered via a subdermal rod to function as an ectopic ovarian hub, supplementing or replacing the ovary’s hormone output.
Gameto’s IVM program has been approved for use in Australia and parts of Latin America. It is still undergoing phase 3 testing in the U.S. Through the deal, Gameto taps into Ferring’s global presence in reproductive medicine and make more comfortable fertility treatment available to women across the world.
[This post is for educational purposes only. It reflects my own analysis of publicly available information, does not constitute legal advice, and does not create an agent-client relationship. Views expressed are my own, not those of any employer or client.]
